Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and thereby acts on the microtubule structure and function of the cell. Thereby the microtubular function is stabilized and ultimately cause cell death.
Therapeutic Target Annual Diagnoses (est.)
Breast cancer (metastatic) 2.1 million worldwide

How it Works

Ixempra® seeks to block the ability of cells to modify the internal ‘skeleton’ that they need to divide and multiply. When the skeleton is unable to change, the cancer cells cannot divide and eventually die. Both cancer cells and non-cancer cells, such as nerve cells, is affected by Ixempra®, which could cause side effects.

Clinical Trials

Already before Oncology Venture obtained the option to in-license Ixempra®, more than 80 studies involving ixabepilone have been completed.


A molecular model of ixabepilone.

Ixempra® DRP

According to Oncology Venture’s analysis patients benefiting from Ixempra® can be identified by using Oncology Venture’s ixabepilone-specific DRP® companion diagnostic. A dedicated DRP® for Ixempra® is still to be developed.


Oncology Venture obtained the option to in-license the European rights to Ixempra® from R-Pharm U.S., LLC. in April 2019.


Ixempra® belongs to a group of medicines called ‘potheilones’.

Want to keep updated on news from Oncology Venture? Sign up to our press releases here: